Bladder Cancer: Highlights from 2006 eulogo1

By: Antonio Alcarazlowast

European Urology Supplements, Volume 6 Issue 12, July 2007, Pages 737-744

Published online: 01 July 2007

Keywords: Bacillus Calmette-Gurin, Biomarker, Bladder cancer, EORTC tables, Ifosfamide, Interferon-alpha, Invasive, Laparoscopy, Nedaplatin, NMP-22, Paclitaxel, Superficial, Survivin

Abstract Full Text Full Text PDF (478 KB)



This paper provides an overview of the most relevant findings on bladder cancer (BCa) presented at the 2006 annual meetings of the European Association of Urology, American Urological Association, and the American Society of Clinical Oncology.


Experts in the field of BCa selected and discussed relevant new findings in BCa during a closed meeting in Marbella, Spain. Furthermore, the participants’ opinions on representative clinical cases were assessed via interactive voting. Voting results were commented on by an expert panel.


Many studies examined the diagnostic and prognostic value of the biomarkers survivin and nuclear matrix protein-22, but results were not consistent. With respect to superficial BCa, a major revelation was the introduction of the European Organisation for Research and Treatment of Cancer tables to calculate the risk for recurrence and progression of superficial BCa patients. In addition, one study showed that Bacillus Calmette-Guérin+interferon-alpha might be a good alternative treatment for patients with recurrent superficial BCa. For patients with minimally invasive BCa who had undergone radical transurethral resection, a bladder-sparing treatment was cautiously suggested. For those with recurrent urothelial cancer, one study presented a new salvage chemotherapy consisting of paclitaxel, ifosfamide, and nedaplatin. Finally, two studies demonstrated that there was no difference in oncologic outcome between patients who underwent open or laparoscopic radical cystectomy or nephroureterectomy.


Many interesting new findings in the field of BCa have been presented at 2006 urologic/oncologic meetings, which aim to improve the diagnosis and treatment of patients with BCa.

Take Home Message

This paper reviews the most relevant new data on bladder cancer (BCa) presented at the 2006 urologic/oncologic meetings, comprising diagnostic and prognostic tools and second-line treatment for superficial BCa, new treatment strategies for invasive BCa, and open versus laparoscopic surgery.

Keywords: Bacillus Calmette-Guérin, Biomarker, Bladder cancer, EORTC tables, Ifosfamide, Interferon-alpha, Invasive, Laparoscopy, Nedaplatin, NMP-22, Paclitaxel, Superficial, Survivin.


Department of Urology, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain

lowast Tel. +34 93 227 5545; Fax: +34 93 227 5545. Please visit to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.

Place a comment

Your comment *

max length: 5000